| abstract |
Provided is an immune cell mixture comprising an immune cell genetically modified with a chimeric antigen receptor targeting CD19 and an immune cell genetically modified with a chimeric antigen receptor targeting PSMA and an application thereof. The chimeric antigen receptor targeting CD19 and the chimeric antigen receptor targeting PSMA each comprises an antigen-binding domain, a transmembrane domain, a costimulatory signaling region, a CD3ΞΆ signaling domain, and an inducible suicide fusion domain in tandem arrangement. The chimeric antigen receptors specifically recognize tumor surface antigens CD19 and PSMA. Compared to using other single chimeric antigen receptor T cells, using the combination of CAR-T cells targeting two antigens achieves better therapeutic effects, makes CD19 escape not easy to occur, and allows the disease to be easily relieved. |